Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.

摘要: Although gastrointestinal stromal tumors (GISTs) are rare, with an incidence of 1/100000 per year, they the most common sarcomas in peritoneal cavity. Despite considerable progress diagnosis and treatment GIST, about half all patients estimated to experience recurrence. With only two drugs, sunitinib regorafenib, approved by Food Drug Administration, selecting options after imatinib failure coordinating multidisciplinary care remain challenging. In addition, physicians across Middle East face some additional unique challenges such as lack published local data from clinical trials, national disease registries regional scientific research, limited access treatment, standardization care, mutational analysis. global guidelines set a framework for management there no standard guide practice resource-limited environment. Therefore, group 11 experienced medical oncologists Gulf Levant region, part Rare Tumors Gastrointestinal Group, met over period one year conduct narrative review GIST describe gaps patient essential step proposing recommendations.